Q1 2020 Saw Normal Reductions In Presidential Election Year Lobby-Spends…
April 24, 2020

Even so, the ten year general trend line — as adjusted for overall size of company — reveals that Pfizer still outspends almost all other big pharmas / general life-sciences companies.

Amgen spends disproportionately large amounts as well — in the biologics / bio-science end of the pool. . . so we will highlight below where that money was deployed. [We’ve been tracking this continuously, since early 2013.]

. . . .▲ Biosimilars, no specific bill; Prescription drug value issues, no specific bill; FDA issues, no specific bill; Issues related to International Pricing Index (IPI), no specific bill; S. 657 Drug Price Transparency Act; S. 658 Accelerated Drug Approval for Prescription Therapies Act; S. 660 Efficiency and Transparency in Petitions Act; S. 1895, Lower Health Care Costs Act [a comprehensive bill designed to improve healthcare transparency and reduce healthcare costs, including prescription drugs]; H.R. 1499, Protecting Consumer Access Generic Drugs Act; H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings (DRUGS) Act; S. 1169, Ensuring Timely Access to Generics Act; S. 1617, Second Look at Drug Patents Act; H.R. 1520, Purple Book Continuity Act; S. 977, Transparent Drug Pricing Act; S. 102, Prescription Drug Price Relief Act; S. 659, Biologic Patent Transparency Act; H.R. 1503, Orange Book Transparency Act; H.R. 2296, Fair Accountability and Innovative Research (FAIR) Drug Pricing Act; S. 1664, Prescription Drug Price Reporting Act S.659 – the Biologics Patent Transparency Act; Supply Chain Issues, no specific bill. . .

▲ Medicare Part B coverage and reimbursement issues; Issues related to International Pricing Index (IPI), no specific bill; Coding and reimbursement for biologics/biosimilars; Issues related to Part D redesign, no specific bill; Issues related to Part D rebate reform, no specific bill; Medicare Part D access issues for plan year 2020, no specific bill; S. 1676 Chronic Kidney Disease Improvement in Research and Treatment Act; Transitional drug add-on payment (TDAPA), dialysis bundled payment system issues; H.R. 2296/S 1391 FAIR Drug Pricing Act; S. 1416 Affordable Prescriptions for Patients Act; Issues related to Direct to Consumer Advertisement; Issues related to Biosimilars, no specific bill; Prescription drug value issues, no specific bill; S. 1664, Prescription Drug Price Reporting Act; H.R. 3 – Lower Prescription Drug Costs Now Act; H.R. 2693/S. 283 – Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2019; Issues related to the Center for Medicare & Medicaid Innovation; S. 2543 Prescription Drug Pricing Reduction Act; Section 210- Applying Medicaid Drug Rebate Requirement to Drugs Provided as Part of Outpatient Hospital Services; H.R. 19/S. 3129 Lower Costs, More Cures Act; 2021 Notice of Benefit and Payment Parameters (NBPP) proposed rule and cost-sharing assistance; HR 748 Coronavirus Aid, Relief, and Economic Security (CARES) Act and access to Part B medicines at home; Issues related to the 340B program, no specific bill. . .

▲ International Tax issues including regarding Public Law 115-97, Tax Cuts and Jobs Act; Tax issues related to Puerto Rico; Issues related to OECD negotiations on the taxation of global income. . .

▲ S. 124 Preserve Access to Affordable Generics Act; Issues related to drug patents and exclusivities (no bill); H.R. 1520, Purple Book Continuity Act of 2019; H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019; S. 1224, The Stop STALLING Act; S. 1416, The Affordable Prescriptions for Patients Act, on product hopping and patent thicketing; S.659 – the Biologics Patent Transparency Act; H.R. 938 Bringing Low-cost Options and Competition while Keeping Incentives for New Generics; H.R. 5133 Affordable Prescriptions for Patients Through Promoting Competition; H.R. 3991 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act; H.R. 2374 Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act; H.R. 2375 Preserve Access to Affordable Generics and Biosimilars Act. . . .

Enlarged:

Now you know. Be excellent to one another. Grins. . . .

नमस्ते